Leveraging natural killer cells for cancer immunotherapy
| Autor: | William J. Murphy, Ethan G. Aguilar, Steven K. Grossenbacher |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment Adoptive Review Immunotherapy Adoptive rituximab Cancer immunotherapy Neoplasms Monoclonal cetuximab Killer Cells Immunology and Allergy Cancer Clinical Trials as Topic Effector bortezomib Antibodies Monoclonal Pharmacology and Pharmaceutical Sciences CAR Killer Cells Natural trastuzumab medicine.anatomical_structure Oncology 5.1 Pharmaceuticals Natural Neoplastic Stem Cells immunotherapy Development of treatments and therapeutic interventions Biotechnology cancer stem cell medicine.drug_class lenalidomide Clinical Sciences Immunology Antineoplastic Agents Monoclonal antibody Antibodies Natural killer cell Vaccine Related 03 medical and health sciences Cancer stem cell medicine Animals Humans radiotherapy Innate immune system 5.2 Cellular and gene therapies Animal business.industry Immunotherapy natural killer cell medicine.disease cytokines Disease Models Animal 030104 developmental biology Disease Models Immunization business |
| Zdroj: | Immunotherapy, vol 9, iss 6 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2017-0013 |
| Popis: | Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|